In the latest edition of the Guidelines International Series, we explore the most recent guidelines published by the prestigious International Myeloma Working Group (IMWG). The IMWG is well known for its series of guidelines and recommendations that focus on the management and treatment of multiple myeloma and related disorders. With numerous research studies and treatment guidelines under its belt, the IMWG is a leading authority in the field.
Consistently, the IMWG releases a wide range of international guidelines, recommendations, consensus statements, and more, each with specific objectives aimed at enhancing the understanding of myeloma for both healthcare providers and patients. In this edition, we will provide an overview of the IMWG Guidelines and recommendations from the past five years, offering valuable insights into the advancements in myeloma treatment and management.
IMWG Guidelines/Recommendations
- Management and Response Assessment of Chimeric Antigen Receptor T-Cell Therapy in Clinical Practice for Relapsed and Refractory Multiple Myeloma
- Published: May 28, 2024
- Optimal Use of T-Cell-Engaging Bispecific Antibodies in Multiple Myeloma
- Published: May 16, 2024
- Management of Multiple Myeloma-Related Renal Impairment
- Published: July 23, 2023
- Infection Prevention in Multiple Myeloma
- Published: February 11, 2022
- Treatment of Multiple Myeloma-Related Bone Disease
- Published: March 11, 2021
- Treatment of Relapsed and Refractory Multiple Myeloma
- Published: March 8, 2021
We trust that you found these guidelines as fascinating as we did. Exploring international society guidelines can expand our comprehension of recommendations beyond our own, thus enhancing our knowledge base. Please inform us if there are any international societies you would like us to investigate and don’t forget to sign up for alerts and stay informed on the latest published guidelines and articles.
Copyright © 2024 Guideline Central, All Rights Reserved.